Zota Health Care IPO

Zota Health Care IPO

Zota Health Care IPO

Zota Health Care IPO

Zota Health Care Ltd (ZHCL) started operations in 2000 and is a fast growing pharmaceutical company with a portfolio of formulations including Nutraceuticals and Ayurvedic offerings that are available in many Asian, African, Latin American and CIS countries in addition to India. Over the years, the company has built a steady position with a consistent growth of revenue in domestic operations from INR32 crore in 2012 to INR58 crore in 2016.

ZHCL has currently applied for patent for 19 unique formulations from which it has been granted approvals for 6 formulations. The company is actively expanding its presence in the digital space with the launch of its mobile application for its Nutravedic division. Additionally, it has acquired marketing rights of Astra-Idl Ltd, for three years to strengthen its position in the generic market segment.

Zota has an impressive product line that boasts of products in the form of Tablets, Capsules, Oral Liquids, Dry Powders, Injectable, Oral Liquid Sprays, Ointments, Creams, Lotions, Medicated Soaps, Eye / Ear / Nasal Drops, Ayurvedic Products, Tooth Gels, Mouth Wash, Gum Paint, Shampoos, Prefilled Syringes, Nutraceuticals, Cosmetics with 21 divisions offering products under various categories and sub categories.

Promoters of Zota Health Care – Ketankumar Zota, Manukant Zota, Himanshu Zota and Kamlesh Zota

Zota Health Care IPO details

Subscription Dates27 Apr - 2 May 2017
IPO Price bandINR121 - 125 per share
Fresh issue 3,180,000 shares (INR39.75 crore at upper band)
Offer for sale 1,500,000 shares (INR18.75 crore at upper band)
Total IPO size4,680,000 shares (INR58.5 crore at upper band)
Minimum bid (lot size)1,000 shares
Face Value INR10 per share
Retail Allocation50%
Listing OnNSE Emerge platform


Zota Health Care's financial performance (in INR crore)

 FY2012FY2013FY2014FY2015FY20169M FY2017
Total revenue38.243.950.256.564.856.2
Total expenses35.240.145.550.157.050.3
Profit after tax2.

Zota Health Care IPO Subscription Details


Subscription (no. of times)

Day 10.40
Day 21.43
Day 315.68

Zota Health Care Contact Details

Zota Health Care Limited
2/896, Hira Modi Street, Sagrampura
Surat - 395 002

Phone: +91 261 233 1601
Email: [email protected]
Website: www.zotahealthcare.com

Zota Health Care Valuation (latest FY)

Earnings Per Share (EPS): INR3.61

Price/Earnings (P/E) ratio: 33.5 - 34.6

Return on Net Worth (RONW): 24.05%

Net Asset Value (NAV): INR15.01 per share

Registrar of Zota Health Care IPO

Satellite Corporate Services Pvt Ltd
B-302, Sony Apartment, 90 feet road,
Jarimari, Sakinaka, Mumbai – 400 072
Maharashtra, India

Phone: +91 22 2852 0461
Fax: +91 22 2851 1809
Email: [email protected]
Website: www.satellitecorporate.com

Zota Health Care IPO Allotment Status

Zota Health Care IPO allotment status is now available on Satellite Corporate Services' website. Click on this link to get allotment status.


IPO Opening Date: 27 April 2017

IPO Closing Date: 2 May 2017

Finalization of basis of allotment: 5 May 2017

Initiation of refunds: 8 May 2017

Credit of shares in demat accounts: 9 May 2017

Listing Date: 11 May 2017

Listing Price on NSE SME: INR129.9 per share (up 3.9% from IPO price)

Closing Price on NSE SME:  INR127 per share (up 1.6% from IPO price)


  1. how to sell share if we selected for allotment ?
    if there is no any buyer who want to buy zota then how to sell our shate ???
    anyone have idea ??

  2. Please be very careful while investing in any SME IPO.

    Issues are highly priced.

    Dont get exited by just seeing listing price or subject to allotment amount as it may be a trap for investors.

    *Zota Healthcare NSE SME IPO*
    Last Date – 02/05/2017
    Price – Rs 125
    Lot – 1000 shares
    App Amt- Rs 1,25,000/-

    Promoter costing is less than 0.10 paisa per share and offering shares to public at Rs 125/share.

    Lot of money is spent on advertisement in CNBC, Divyabhaskar and also outdoor hoardings. Due to this type of marketing, retail subscription would be more than 10 times.

    As it’s momentum in market all offerings are getting better listing but this is not only parameter.

    May get some listing gain but not that encouraging.

    Probability of losing money is equal to listing gain profit.

    Therefore one should avoid applying in this IPO.

  3. SME IPOs need to keep their prices reasonable as risk is very high in them. This one is expensive at PE of more than 30.